Pancreatic cancer is among the leading causes of cancer-related deaths with extremely poor prognosis. Thus, novel and effective therapies need to be developed to improve the poor survival rates of patients with advanced pancreatic cancer. Pectolinarigenin, a flavonoids compound, has been shown to possess numerous biologic activities such as anti-inflammation and anti-cancer. However, the function and mechanism of pectolinarigenin in pancreatic cancer are still not well understood. We evaluated the antitumor effects of pectolinarigenin, an active component of a medicinal plant. Pectolinarigenin exerted a strong antitumor effect in pancreatic cancer cell lines. Colony formation assay and wound healing assay indicated that pectolinarigenin inhibited cell viability and cell migration. Treatment with pectolinarigenin induced apoptosis and decreased phosphorylation of STAT3. Pectolinarigenin modulates the STAT3 signaling module, thereby inducing cytotoxicity in pancreatic cancer cells. This result verifies the potential use of pectolinarigenin as a new therapeutic agent for the treatment pancreatic cancer.
Pancreatic cancer (PC) is the fifth leading cause of cancer-related deaths in the United States, after lung, prostate, breast, and colon cancer [1, 2] . Despite advances in surgery and multiagent chemotherapy, less than 20% of patients have operable PC at diagnosis, and 80% of patients with localized PC experience recurrence within 3 years after surgery [3] . Thus, novel therapeutic approaches for the treatment of PC need to be developed.
Signal transducer and transcription activator 3 (STAT3) is an important transcription factor involved in the cell growth, survival, apoptosis, angiogenesis, and metastasis of cancer cells [4] [5] [6] . Recent studies have found that STAT3 is constitutively activated in many cancers, including head and neck squamous cell carcinoma, breast cancer, ovarian cancer, lung cancer, and leukemia [7] [8] [9] . Constitutive activation of STAT3 by phosphorylation of Tyr705 has been reported in 30-100% of human tumor specimens, as well as in many PC cell lines [10] . Several studies have suggested that aberrant activation of STAT3 in PC is functionally important [6, 11] .
Pectolinarigenin has recently been reported to be an active component of a medicinal plant [12] . Pectolinarigenin exhibits significant anti-inflammatory activity, has a wide range of applications in clinical medicine [13] . Moreover, it has shown potential for application in the treatment of human malignancies and has attracted considerable attention as a candidate compound for chemotherapy [14, 15] . Pectolinarigenin exhibits antitumor activity, but its underlying molecular mechanism remains poorly understood. Our in-depth study of the antitumor activity of pectolinarigenin for PC demonstrated that pectolinarigenin could reduce PC cell growth and induce apoptosis. Findings suggested that pectolinarigenin could inhibit cell migration. Further studies were performed to elucidate the mechanisms underlying its inhibition of cell viability and promotion of cell apoptosis. We found that pectolinarigenin could be used as an anticancer agent in PC cells via inhibition of STAT3 signaling pathway.
Cell growth effects of pectolinarigenin in pancreatic cancer cells:
We evaluated the inhibitory effects of pectolinarigenin in PC cells (Patu 8988 and BxPC-3). PC cells were incubated with pectolinarigenin at different concentrations for 48 h. As shown in Figure 1 , pectolinarigenin dose-dependently reduced cell viability in Patu 8988 and BxPC-3. These data indicated that pectolinarigenin markedly inhibited the cell growth of PC cells.
Pectolinarigenin inhibited colony formation in pancreatic cancer cells: Colony-forming ability characterizes the independent survival and environmental adaptability of cancer cells [16] . We then investigated the effect of pectolinarigenin on the clonogenic survival of the PC cells by colony formation assay in plates. As shown in Fig. 2 , pectolinarigenin dose-dependently inhibited the clonogenic survival of Patu 8988 cells after 7 days of treatment. These findings indicated that pectolinarigenin exerted a potent inhibitory effect on PC cell growth in vitro and could potentially be used for the treatment of PC. 
Pectolinarigenin induced cell apoptosis in pancreatic cancer cells:
We then evaluated the role of apoptosis in pectolinarigenininduced cell apotosis by staining with Annexin V-fluorescein isothiocyanate and PI. BxPC-3 cells were treated with pectolinarigenin (10, 20 and 50 μM) for 48 h and then stained with Annexin V and PI for apoptosis analysis using flow cytometry. As observed in Figure 3 , the exposure of BxPC-3 to pectolinarigenin at various concentrations for 48 h dose-dependently increased the number of apoptotic cells.
Inhibition of STAT3 by pectolinarigenin in BxPC-3 pancreatic cancer cells:
STAT3 is constitutively activated and its prognostic value has been associated with phosphorylated STAT3-signatures in PC [17] . As such, targeting STAT3 signaling with small molecule inhibitors is an emerging therapeutic strategy for PC [18] . We thus performed Western blot analysis in PC cells to examine whether pectolinarigenin could inhibit STAT3 expression. As shown in Figure 4 , Western blot analysis indicated that pectolinarigenin inhibited STAT3 phosphorylation in a time-and dose-dependent manner. 
Figure 4: Inhibition of STAT3 by pectolinarigenin in BxPC-3 pancreatic cancer cells. (A)
BxPC-3 cells were treated with pectolinarigenin at different concentrations (30, 50, and 100 μM). Total protein was extracted, and the expression levels of P-STAT3, STAT3, and GAPDH proteins were detected by Western blot analysis. (B) BxPC-3 cells were treated with pectolinarigenin (50 μM) for different lengths of time (0, 2, 4, 6, 8, 12, and 24 h). Total protein was extracted, and the expression levels of P-STAT3, STAT3, and GAPDH proteins were detected by Western blot analysis.
Pectolinarigenin decreased cell migration of pancreatic cancer cells:
To evaluate the inhibitory effects of pectolinarigenin on cell migration, we adopted a scratch wound model. Wound areas were marked and photographed at 0 and 24 h, respectively. Compared with the control group in BxPC-3 cells and Patu 8988 cells, the cells treated with pectolinarigenin at different concentrations (10, 20 and 50 μM) migrated into the wound with a significantly decreased distance between the edges after 24 h, as shown in Figure 5 . PC is currently the fifth leading cause of cancer-related deaths in the United States and is projected to rank higher, second to lung cancer by 2030 [2] . PC shows a very high mortality rate and has generally advanced to untreatable status prior to detection [19] . Despite an aggressive approach combining both chemotherapy and radiotherapy, about 25-30% of patients with local recurrence and/or distant metastases still fail [20] . Gemcitabine is used to treat patients with PC, however, the response rate is below 12% and is associated with increased toxicity [21, 22] . The prognosis for patients with metastatic disease is poor [23] . Thus, new therapeutic strategies need to be explored to improve the treatment outcome. The findings in the present study suggest that pectolinarigenin exhibits cytotoxic effects and dose-dependently reduces cell viability, as shown in Figure 1 . Cancer metastasis is the leading cause of cancer-related deaths and is directly associated with cancer progression, resistance to anticancer therapy, and poor patient survival, which is responsible for most cancer-associated mortality [24] . Migration is a critical event in cancer progression and metastasis [25] , thus, the inhibitory effect of pectolinarigenin on cell migration was evaluated. The results of our study indicated that pectolinarigenin significantly blocked BxPC-3 and Patu 8988 cell migration, as denoted by a scratched area in Figure 5 . In addition, colony formation assay demonstrated that pectolinarigenin exerts good inhibitory effects on PC cell growth ( Figure 2 ). As shown in Figure 3 , pectolinarigenin induced prominent cell apoptosis in PC cells. Pectolinarigenin division has a wide range of significant applications in clinical medicine, but the molecular mechanism underlying its antitumor activity is poorly understood [12] . The results of the study indicate that pectolinarigenin can suppress STAT3 phosphorylation time-dependently and dose-dependently in PC, as shown in Figure 4 .
This study was conducted only in vitro. As some compounds exhibit potent antitumor activities in vitro but not in vivo, the present study, which indicates that pectolinarigenin can inhibit PC cell growth, requires further research. In summary, we evaluated the antitumor activity of pectolinarigenin for PC. We also demonstrated that pectolinarigenin could inhibit PC cell growth by inhibiting STAT3 phosphorylation. Our current study may represent a novel and effective therapeutic strategy to improve the prognosis of patients with PC.
Experimental
Cell culture and antibodies: Human PC cell lines (Patu 8988 and BxPC-3) were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). BxPC-3 was routinely cultured in Roswell Park Memorial Institute (RPMI)-1640 (Gibco/BRL life Technologies, Eggenstein, Germany) and Patu 8988 was cultured in M199 (Gibco, Eggenstein, Germany). All cell lines were supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 1% penicillin/streptomycin solution at 37 °C in a humidified atmosphere of 5% CO 2 . Antibodies, such as P-STAT3 and STAT3, were purchased from Cell Signal Technology (Danvers, MA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Pectolinarigenin was purchased from Sigma-Aldrich (St. Louis, MO).
MTT assay: Cells were seeded into 96-well plates at a density of 5 × 10 3 cells per well in 100 μL of the corresponding medium overnight. The cells were then treated with drugs at different concentrations for 48 h. Subsequently, they were treated with a fresh solution of MTT (5 mg/mL) for 4 h at 37 °C. The crystals were finally solubilized in a dimethyl sulfoxide (DMSO) solution, and absorbance was recorded using a multi-well plate reader at 490 nm.
Western blot assay:
After treatment, the cells were collected, and total protein extraction was conducted. Protein concentration in all specimens was determined using the Bradford Protein Assay Kit. Protein specimens (30-100 μg) were subjected to (10%-15%) sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene fluoride membrane. After being blocked in blocking buffer (5% milk in Tris-buffered saline containing 0.05% Tween 20) for 1.5 h at room temperature, the membranes were incubated with different primary antibodies overnight at 4 °C. The membranes were then washed with trisbuffered saline containing 0.1% Tween 20 (TBST) and then reacted with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The immunoreactive bands were visualized using an enhanced chemiluminescence kit. The density of the immunoreactive bands was analyzed using the Image J software (National Institute of Health, MD).
Scratch wound model:
PC cells (5 × 10 5 cells/well) were seeded in 6-well plates and allowed to adhere overnight. At 80-90% confluence, a "reference line" was scratched at the bottom of the plate by using a sterile 10 μL pipette tip. After being washed with phosphate buffer saline (PBS) thrice, cells were further incubated with pectolinarigenin (10, 20, and 50 μM) or a vehicle (DMSO) in a calcium-free medium to examine cell migration in the absence of cell cell growth. Photomicrographs of cells migrating across the reference line were taken in different fields with a Canon digital camera (Canon, Japan) after treatment at 0 and 24 h, respectively. The rate of mobility was quantified by the migrated distance of cells moved from the reference lines toward the center, compared with that of the control. All experiments were repeated 3 times.
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Clonogenic assay:
A total of 500 cells per well were seeded into a 6-well plate with 2 mL medium overnight. The cells were then pretreated with pectolinarigenin or DMSO for 8-12 h. After treatment, the cells were washed with PBS twice and then transferred into a fresh medium to allow cells to grow for 7 days. Colonies were washed with PBS and then fixed with 4% methanol for 15 min at room temperature. The cells were washed with PBS twice and then stained with 1% crystal violet (25% methanol) for 10 min at room temperature. Each experiment was conducted for 3 independent experiments.
Flow cytometry: Apoptosis was evaluated using Annexin V/PI Kit (BD Biosciences Pharmingen, Franklin Lakes, NJ). Exponentially growing cells were seeded on 6-well plates and then treated with pectolinarigenin (10, 20, and 50 μM) or DMSO (vehicle control, final concentration of 0.1%) for 48 h. The treated cells were harvested and stained with Annexin V and propidium iodide (PI).
Flow cytometry was conducted using FACSCalibur (BD Biosciences, Franklin Lakes, NJ).
Statistical analysis:
All data were presented as mean ± standard deviation (SD) for numeric variables and as frequency (%) for categorical variables. Comparisons were conducted with one-way analysis of variance (ANOVA) by post hoc Scheffe's test among different experimental groups. Statistical analysis was performed with the Prism software (GraphPad Inc., Carlsbad, CA, USA). A value of P < 0.05 was considered statistically significant.
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